Crawford Lake Capital Management LLC acquired a new stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 68,877 shares of the biopharmaceutical company’s stock, valued at approximately $1,481,000. Crawford Lake Capital Management LLC owned approximately 0.11% of Dynavax Technologies as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Cubist Systematic Strategies LLC raised its position in shares of Dynavax Technologies by 54.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC raised its position in shares of Dynavax Technologies by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,700 shares during the period. Legal & General Group Plc raised its position in shares of Dynavax Technologies by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares during the period. Bank of America Corp DE raised its position in shares of Dynavax Technologies by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 456 shares during the period. Finally, Wall Street Access Asset Management LLC acquired a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $124,000. Hedge funds and other institutional investors own 70.61% of the company’s stock.

Shares of Dynavax Technologies Corporation (DVAX) opened at $17.40 on Wednesday. Dynavax Technologies Corporation has a 1 year low of $3.70 and a 1 year high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same period last year, the firm earned ($0.90) EPS. The firm’s revenue was down 68.8% compared to the same quarter last year. analysts forecast that Dynavax Technologies Corporation will post -1.72 EPS for the current fiscal year.

A number of analysts have recently weighed in on DVAX shares. William Blair reiterated an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies in a research report on Wednesday, August 9th. Cowen reiterated an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies in a research report on Thursday, August 10th. Royal Bank Of Canada reiterated a “buy” rating and set a $26.00 price target on shares of Dynavax Technologies in a research report on Friday, September 1st. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, Cantor Fitzgerald started coverage on Dynavax Technologies in a research report on Friday, September 15th. They set an “overweight” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $25.17.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/crawford-lake-capital-management-llc-acquires-new-position-in-dynavax-technologies-corporation-dvax/1746829.html.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.